Mass. Movers

Analysts raise price target on Insulet

A diabetic tests his blood-sugar level.
Associated Press/File 2009
A diabetic tests his blood-sugar level.

Canaccord Genuity analysts set a $37 price target on Insulet Corp. stock, reported. The firm currently rates the stock a “buy.” “Management has positively commented . . . that new patient growth remains robust,” analysts wrote. In the most recent quarter, revenue rose 20 percent, compared to the same quarter last year. Bedford-based Insulet makes the OmniPod Insulin Management System for people with insulin-dependent diabetes.